PapersPMID:30871514
Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
- findings
- 3
- compound
- 1
- endpoints
- 3
- Study, every finding
- RCT
- Dose studied, every finding
- 3 g/day, two 0.5 g capsules per meal with food, for 3 months
- Population, every finding
- overweight or obese adults (30-60 years) with non-alcoholic fatty liver disease by ultrasonography; both arms given lifestyle advice (5% weight-loss diet and moderate aerobic activity)
What moved
How to read these marks →“In other words, GC in comparison with placebo significantly elevated irisin, HDL-c, and QUICKI and reduced FBI, HOMA-IR, TG, and LDL-c (P < 0.05).”
- Increases HDL cholesterol
moderate
- Decreases HOMA-IR
moderate
- Decreases triglycerides
moderate
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Overweight or obese (25 <= BMI < 35) NAFLD patients aged 30-60, NIOC central hospital, Tehran; whole green cardamom powder (Elettaria cardamomum (L.) Maton, voucher PMP-669, Samex agency India) 3 g/day as 0.5 g capsules vs toast powder placebo for 3 months, with lifestyle advice to both arms; modified-ITT analysis of 87
- Participants
- 87
- Comparator
- placebo
- Duration
- 91 days
- Endpoints measured
- 72